This inventor holds 4 USPTO granted patents. Top assignees: Aptalis Pharma Canada Inc., Aptalis Pharma Canada Ulc, Axcan Pharma Inc.. Active years: 2009-2018.
Location History:
- Quebec, CA (2009 - 2013)
- Repentigny, CA (2018)
Company Filing History:
Years Active: 2009-2018
Title: Carl Gauthier: Innovator in Pharmaceutical Solutions
Introduction
Carl Gauthier is a notable inventor based in Canada, recognized for his contributions to the field of pharmaceuticals. He holds a total of 4 patents, showcasing his innovative approach to drug formulation and delivery systems. His work primarily focuses on improving patient comfort and efficacy in medication administration.
Latest Patents
One of Gauthier's latest inventions is a mesalamine rectal suppository designed to enhance comfort during use. This invention includes various embodiments, such as a suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, with a drug load ranging from 35% to 50%. Another embodiment features mesalamine with a tap density between 600 to 800 g/L, combined with a hard fat that has a melting point of 32 to 35.5°C. Additionally, the invention outlines methods for preparing mesalamine suppositories and determining their dissolution parameters, ensuring effective treatment options for patients.
Career Highlights
Throughout his career, Carl Gauthier has worked with prominent companies in the pharmaceutical industry, including Aptalis Pharma Canada Inc. and Axcan Pharma Inc. His experience in these organizations has contributed significantly to his expertise in drug formulation and development.
Collaborations
Gauthier has collaborated with various professionals in the field, including Yves Dumoulin and David Powell. These partnerships have further enriched his work and innovation in pharmaceutical solutions.
Conclusion
Carl Gauthier's contributions to the pharmaceutical industry through his innovative inventions, particularly in mesalamine suppositories, highlight his commitment to improving patient care. His work continues to influence the development of effective medication delivery systems.